Immatics NV: Taking Off On A PRAME Rocketship
Source: SeekingAlpha
2025-06-04 10:05:58 ET
Summary
- Immatics NV's lead asset, IMA203, shows promising early efficacy in melanoma, including difficult-to-treat uveal melanoma, per updated ASCO data.
- The company remains well-capitalized, with sufficient liquidity to fund operations for at least 3-4 years at current burn rates.
- Despite strong early data, collaboration revenue is variable and operating cash flow remains negative, highlighting ongoing financial risks.
- Engineered cell therapies face unique commercialization challenges, tempering near-term optimism despite encouraging clinical progress.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Immatics NV: Taking Off On A PRAME Rocketship
Immatics N.V.
NASDAQ: IMTX
IMTX Trading
-0.61% G/L:
$11.37 Last:
87,110 Volume:
$11.48 Open:
IMTX Latest News
May 12, 2026 07:00:00 am
Immatics Announces First Quarter 2026 Financial Results and Business Update
April 21, 2026 10:25:55 am
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
IMTX Stock Data
$1,341,978,928
63,814,383
N/A
32
N/A
Biotechnology & Life Sciences
Healthcare
DE
Tbingen
